316 related articles for article (PubMed ID: 18681089)
1. The effects of the nasal antihistamines olopatadine and azelastine in nasal allergen provocation.
Pipkorn P; Costantini C; Reynolds C; Wall M; Drake M; Sanico A; Proud D; Togias A
Ann Allergy Asthma Immunol; 2008 Jul; 101(1):82-9. PubMed ID: 18681089
[TBL] [Abstract][Full Text] [Related]
2. Effects of olopatadine hydrochloride nasal spray 0.6% in the treatment of seasonal allergic rhinitis: a phase III, multicenter, randomized, double-blind, active- and placebo-controlled study in adolescents and adults.
Shah SR; Nayak A; Ratner P; Roland P; Michael Wall G
Clin Ther; 2009 Jan; 31(1):99-107. PubMed ID: 19243710
[TBL] [Abstract][Full Text] [Related]
3. Nasal ocular reflexes and eye symptoms in patients with allergic rhinitis.
Baroody FM; Foster KA; Markaryan A; deTineo M; Naclerio RM
Ann Allergy Asthma Immunol; 2008 Mar; 100(3):194-9. PubMed ID: 18426137
[TBL] [Abstract][Full Text] [Related]
4. A comparison of the clinical efficacy of pheniramine maleate/naphazoline hydrochloride ophthalmic solution and olopatadine hydrochloride ophthalmic solution in the conjunctival allergen challenge model.
Greiner JV; Udell IJ
Clin Ther; 2005 May; 27(5):568-77. PubMed ID: 15978305
[TBL] [Abstract][Full Text] [Related]
5. Azelastine and olopatadine in the treatment of allergic rhinitis.
Kaliner MA
Ann Allergy Asthma Immunol; 2009 Nov; 103(5):373-80. PubMed ID: 19927534
[TBL] [Abstract][Full Text] [Related]
6. Effects of intranasal azelastine on the response to nasal allergen challenge.
Saengpanich S; Assanasen P; deTineo M; Haney L; Naclerio RM; Baroody FM
Laryngoscope; 2002 Jan; 112(1):47-52. PubMed ID: 11802037
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of olopatadine hydrochloride nasal spray for the treatment of seasonal allergic rhinitis.
Meltzer EO; Hampel FC; Ratner PH; Bernstein DI; Larsen LV; Berger WE; Finn AF; Marple BF; Roland PS; Wall GM; Brubaker MJ; Dimas C; Potts SL; Silver LH; Barnes JR
Ann Allergy Asthma Immunol; 2005 Dec; 95(6):600-6. PubMed ID: 16400902
[TBL] [Abstract][Full Text] [Related]
8. Effects of a new formulation of olopatadine ophthalmic solution on nasal symptoms relative to placebo in two studies involving subjects with allergic conjunctivitis or rhinoconjunctivitis.
Abelson MB; Gomes PJ; Vogelson CT; Pasquine TA; Turner FD; Wells DT; Robertson SM
Curr Med Res Opin; 2005 May; 21(5):683-91. PubMed ID: 15969867
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the efficacy of combined fluticasone propionate and olopatadine versus combined fluticasone propionate and fexofenadine for the treatment of allergic rhinoconjunctivitis induced by conjunctival allergen challenge.
Lanier BQ; Abelson MB; Berger WE; Granet DB; D'Arienzo PA; Spangler DL; Kägi MK
Clin Ther; 2002 Jul; 24(7):1161-74. PubMed ID: 12182260
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of intranasally applied dimethindene maleate solution as spray in adult volunteers with symptoms of seasonal allergic rhinitis in the Vienna challenge chamber.
Kyrein HJ; Horak F; Nirnberger G; Rehn D
Arzneimittelforschung; 1996 Aug; 46(8):794-9. PubMed ID: 9125281
[TBL] [Abstract][Full Text] [Related]
11. Effects of fexofenadine on the early response to nasal allergen challenge.
Allocco FT; Votypka V; deTineo M; Naclerio RM; Baroody FM
Ann Allergy Asthma Immunol; 2002 Dec; 89(6):578-84. PubMed ID: 12487223
[TBL] [Abstract][Full Text] [Related]
12. Randomized, double-masked comparison of olopatadine ophthalmic solution, mometasone furoate monohydrate nasal spray, and fexofenadine hydrochloride tablets using the conjunctival and nasal allergen challenge models.
Spangler DL; Abelson MB; Ober A; Gotnes PJ
Clin Ther; 2003 Aug; 25(8):2245-67. PubMed ID: 14512132
[TBL] [Abstract][Full Text] [Related]
13. Comparative efficacy of olopatadine 0.1% ophthalmic solution versus levocabastine 0.05% ophthalmic suspension using the conjunctival allergen challenge model.
Abelson MB; Greiner JV
Curr Med Res Opin; 2004 Dec; 20(12):1953-8. PubMed ID: 15701212
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and azelastine hydrochloride 0.05% ophthalmic solution in the conjunctival allergen challenge model.
Spangler DL; Bensch G; Berdy GJ
Clin Ther; 2001 Aug; 23(8):1272-80. PubMed ID: 11558863
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of comfort using olopatadine hydrochloride 0.1% ophthalmic solution in the treatment of allergic conjunctivitis in contact lens wearers compared to placebo using the conjunctival allergen-challenge model.
Brodsky M; Berger WE; Butrus S; Epstein AB; Irkec M
Eye Contact Lens; 2003 Apr; 29(2):113-6. PubMed ID: 12695716
[TBL] [Abstract][Full Text] [Related]
16. Clinical efficacy and pharmacokinetic profiles of intranasal and oral cetirizine in a repeated allergen challenge model of allergic rhinitis.
Korsgren M; Andersson M; Borgå O; Larsson L; Aldén-Raboisson M; Malmqvist U; Greiff L
Ann Allergy Asthma Immunol; 2007 Apr; 98(4):316-21. PubMed ID: 17458426
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of olopatadine hydrochloride nasal spray for the treatment of seasonal allergic rhinitis to mountain cedar.
Ratner PH; Hampel FC; Amar NJ; van Bavel JH; Mohar D; Marple BF; Roland PS; Wall GM; Brubaker MJ; Drake M; Turner D; Silver LH
Ann Allergy Asthma Immunol; 2005 Nov; 95(5):474-9. PubMed ID: 16312171
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of azelastine nasal spray compared with oral cetirizine in patients with seasonal allergic rhinitis.
Corren J; Storms W; Bernstein J; Berger W; Nayak A; Sacks H;
Clin Ther; 2005 May; 27(5):543-53. PubMed ID: 15978303
[TBL] [Abstract][Full Text] [Related]
19. Azelastine eye drops reduce and prevent allergic conjunctival reaction and exert anti-allergic activity.
Ciprandi G; Buscaglia S; Catrullo A; Pesce G; Fiorino N; Montagna P; Bagnasco M; Canonica GW
Clin Exp Allergy; 1997 Feb; 27(2):182-91. PubMed ID: 9061218
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of azelastine nasal spray in seasonal allergic rhinitis patients who remain symptomatic after treatment with fexofenadine.
LaForce CF; Corren J; Wheeler WJ; Berger WE;
Ann Allergy Asthma Immunol; 2004 Aug; 93(2):154-9. PubMed ID: 15328675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
